Although the animal studies in TID have shed some light on the limitation of the rarity of circulating B10 cells, the possibility of therapeutic transfusion of autologous, IL-10-producing, BCR-activated B cells or B10 cells in order to protect human subjects at risk for T1D remains elusive. Here, IL10 is linked to type 1 diabetes mellitus.